20,000 Patients in ECRAID-Base POS

On 16 April, the ECRAID-Base project counted 20,000 patients across its five perpetual observational studies (POS). 

  

This milestone reflects the extraordinary collaboration, commitment, and hard work of our investigators, site staff, clinical operations teams, and everyone involved. Each patient enrolled brings us closer to answering critical questions that can lead to improved treatments. 

 

Our Perpetual Observational Studies 

The POS address infections relevant for antimicrobial resistance, such as ventilator-associated pneumonia and complicated urinary tract infections, as well as for emerging infectious diseases like acute respiratory infections and unexplained febrile illness of likely viral aetiology. There are five POS in ECRAID-Base: 

  • POS-VAP lead by CHU de Limoges, France 
  • POS-cUTI lead by Servicio Andaluz de Salud, Spain
  • POS-ARI-PC lead by University of Oxford, UK
  • POS-ARI-ER lead by University of Oxford, UK
  • POS-Disease X lead by Erasmus Medical Center Rotterdam, the Netherlands

Team effort 

Our heartfelt appreciation for all the study teams, coordinators, and support staff who have gone above and beyond to make this possible. Their expertise, perseverance, and compassionate care are the driving forces behind our success. 

The participation and trust of our patients are also highly essential to the progress of medical research. 

"Reaching 20.000 patients enrolled in the five perpetual observational studies designed and set-up as part of the ECRAID-Base project, demonstrates the capability of the Ecraid warm-base network to facilitate and stimulate international research collaboration. The five studies are ongoing in 248 study sites in 25 European countries and led by five different research teams with operational support from Ecraid."
- Marc Bonten, Ecraid CEO

"With 20.000 patients enrolled across the Perpetual Observational Studies, Ecraid proves its solid recruitment capability. Ecraid is paving the way for the future and is fully ready to embed prospective clinical trials in its different POS in collaboration with academic and industry partners."
- Bruno François, Lead Investigator POS-VAP, CHU Limoges


"We cannot thank the research teams at the POS(-cUTI) sites enough – this great milestone would have not been possible without them!"
- Jesús Rodríguez Baño, Lead Investigator POS-cUTI, University Hospital Virgen Macarena

What’s Next 

With 20,000 participants now enrolled, POS studies continue to gather essential data. We remain committed to maintaining the highest standards of quality, ethics, and patient care as we advance toward our study goals. 

Find out more about our perpetual observational studies here, or read  this peer-reviewed article.